

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A directly tabletable gastroresistant spheroid, ~~characterized in that it~~ which comprises:

[[>]] (i) a core comprising one or more active principles, directly coated with

[[>]] (ii) a flexible and deformable film comprising an enteric polymer and a mixture of saturated and/or unsaturated polyglycosylated glycerides whose fatty acids contain at least 8 carbon atoms,

[[>]] (iii) a water-dispersible outer layer comprising at least one disintegrant.

2. (Currently Amended) The spheroid of claim 1, ~~characterized in that~~ wherein the core comprises one or more active principles selected from ~~those from~~ the group consisting of gastro-intestinal sedatives, antacids, analgesics, anti-inflammatories, coronary vasodilators, peripheral and cerebral vasodilators, antiinfection agents, antibiotics, antivirals, antiparasitics, anticancer agents, anxiolytics, neuroleptics, central nervous system stimulants, antidepressants, antihistamines, anti-diarrheals, laxatives, nutritional supplements, immuno-depressants, hypocholesterolemics, hormones, enzymes, antispasmodics, antianginal agents, medicinal products which influence heart rate, medicinal products

~~used in the treatment of~~ for treating arterial hypertension, antimigraine agents, medicinal products which influence blood clottability, antiepileptics, muscle relaxants, medicinal products ~~used in the treatment of~~ for treating diabetes, medicinal products ~~used in the treatment of~~ for treating thyroid dysfunctions, diuretics, anorexigenic agents, antiasthmatics, expectorants, antitussives, muco-regulators, decongestants, hypnotics, antinausea agents, hematopoietic agents, uricosuric agents, plant extracts, and contrast agents.

3. (Currently Amended) The spheroid of ~~either of claims 1 and 2,~~ characterized in that claim 1, wherein the active principle is selected from proton pump inhibitors, preferably omeprazole, lansoprazole, pantoprazole, pariprazole, leminoprazole or rabeprazole, in their racemic form or in the form of pure enantiomers, themselves in base form or in the form of alkali metal salts; nonsteroidal anti-inflammatories, preferably diclofenac, in the form of bases or of salts; and antibiotics, preferably erythromycin and its derivatives, in the form of bases or of salts.

4. (Currently Amended) The spheroid of ~~one of claims 1 to 3,~~ characterized in that claim 1, wherein the binder is selected from the group consisting of cellulosic polymers, acrylic polymers, povidones, copovidones, polyvinyl alcohols, alginic acid, sodium alginate, starch, pregelatinized starch, sucroses and derivatives thereof, guar gum, polyethylene glycols, and mixtures thereof.

5. (Currently Amended) The spheroid of ~~one of claims 1 to 4,~~
~~characterized in that~~ claim 1, wherein the core optionally comprises a diluent, an
antistat and/or a lubricant.

6. (Currently Amended) The spheroid of ~~one of claims 1 to 5,~~
~~characterized in that~~ claim 1, wherein the enteric polymer is selected from the group
consisting of cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate,
hydroxypropylmethylcellulose succinate phthalate, polyvinyl acetate phthalate,
cellulose acetate trimellitate, carboxymethylcellulose and shellac, which are used
alone or in a mixture.

7. (Currently Amended) The spheroid of claim 6, ~~characterized in that~~
wherein the enteric polymer is a methacrylic acid copolymer.

8. (Currently Amended) The spheroid of ~~one of claims 1 to 7,~~
~~characterized in that~~ claim 1, wherein the fatty acids of the mixture of saturated
and/or unsaturated polyglycosylated glycerides contain from 8 to 18 carbon atoms
(C8-C18).

9. (Currently Amended) The spheroid of claim 8, ~~characterized in that~~
wherein said mixture is a mixture of mono-, di- and triglycerides and of polyethylene
glycol monoester and diester, with a molecular weight of between 200 and 1500, and
optionally of glycerol and of free PEG, and predominantly comprises palmitostearic

acid, said mixture ~~being characterized by~~ having a melting point of between 46.0°C and 51.0°C and a hydrophilic/lipophilic balance (HLB) of 13.

10. (Currently Amended) The spheroid of claim 8, ~~characterized in that~~ wherein said mixture is Gélucire®, in particular Gélucire 50/13.

11. (Currently Amended) The spheroid of ~~claims 1 to 10,~~ claim 1, ~~characterized in that~~ wherein the flexible and deformable film optionally comprises a plasticizer selected from the group consisting of triethyl citrate, acetyl tributyl citrate, triacetin, tributyl citrate, diethyl phthalate, polyethylene glycols, polysorbates, and monoacetylated and diacetylated glycerides, preferably triethyl citrate.

12. (Currently Amended) The spheroid of ~~claims 1 to 11,~~ claim 1, ~~characterized in that~~ wherein the coating composition optionally comprises a surfactant, an antistat and/or a lubricant.

13. (Currently Amended) The spheroid of ~~claims 1 to 12,~~ claim 1, ~~characterized in that~~ wherein the disintegrant is selected from the group consisting of the crosslinked sodium carboxymethylcellulose denoted in the art by the term croscarmellose, crospovidone, sodium carboxymethyl starch, and mixtures thereof.

14. (Currently Amended) The spheroid of ~~claims 1 to 13,~~ claim 1, ~~characterized in that~~ wherein the dispersible outer layer optionally comprises a binder and an auxiliary substance, in particular mannitol.

15. (Currently Amended) A method of preparing ~~the spheroids of claims 1 to 14, characterized in that it comprises~~ a spheroid of claim 1, comprising the following steps:

[[>]] (i) preparing a core comprising one or more active principles and at least one binder;

[[>]] (ii) coating the ~~cores~~ core thus obtained by spraying ~~the~~ it with a coating composition comprising an enteric polymer and a mixture of saturated and/or unsaturated polyglycosylated glycerides whose fatty acids contain at least 8 carbon atoms, preferably from 8 to 18 carbon atoms (C8-C18);

[[>]] (iii) coating the ~~gastroresistant spheroids~~ spheroid thus obtained with a water-dispersible outer layer comprising at least one disintegrant; and

[[>]] (iv) drying the ~~spheroids~~ spheroid.

16. (Currently Amended) The method ~~of preparing~~ of claim 15, ~~characterized in that~~ wherein the core comprising the active principle principle(s) is prepared by granulation, by application to a neutral substance, or ~~else~~ by extrusion with spheronization.

17. (Currently Amended) The method ~~of preparing of claims 15 and 16, characterized in that~~ claim 15, wherein the ~~spheroids are~~ spheroid is prepared in a fluidized-air bed.

18.-22. (Cancelled)